Small Fiber Neuropathy Market is Projected to Gain Healthy Growth by the Expected launch of Emerging Therapies by Major Companies during the Forecast Period (2018-30)
iCrowd Newswire
DelveInsight s
Small Fiber Neuropathy Report delivers an in-depth understanding of the Small Fiber Neuropathy, historical and forecasted epidemiology, and the Small Fiber Neuropathy market trends in the United States EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some Key Highlights from
According to a study conducted in the Netherlands, the average minimum prevalence of SFN is
52.95 cases per 100,000. The study also found that prevalence rates of SFN were higher in men than in women, and that rates in elderly patients were higher than in younger patients.
Amgen today announced that the U.S. Food and Drug Administration has approved LUMAKRAS ™ for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer as determined by an FDA-approved test, who have received at least one prior systemic therapy. LUMAKRAS has received accelerated approval based on overall response rate and duration of response . Continued .
Zai Lab Limited (ZLAB) Reports First Patient Treated in China in Registrational Phase 2 TRIDENT-1 Study of Repotrectinib streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS™ (sotorasib) for the treatment of.
Zai Lab Announces First Patient Treated in China in the Registrational Phase 2 TRIDENT-1 Study of Repotrectinib
May 28, 2021 07:30 ET | Source: Zai Lab Limited Zai Lab Limited
TRIDENT-1 study is enrolling patients with ROS1+ advanced NSCLC and NTRK+ advanced solid tumors.
SHANGHAI and SAN FRANCISCO, May 28, 2021 (GLOBE NEWSWIRE) Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovative commercial-stage biopharmaceutical company today announced dosing of the first patient in China in the registrational Phase 2 portion of TRIDENT-1 study of repotrectinib being conducted by its partner Turning Point Therapeutics, Inc. and Zai Lab in patients with ROS1+ advanced non-small cell lung cancer (NSCLC) and NTRK+ advanced solid tumors. Zai Lab has an exclusive license agreement with Turning Point for the development and commercialization of repotrectinib in Greater China (mainland China, Hong Kong, Macau, and Taiwan).